• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Vaxcyte Stock After Wider Q3 Losses Has The Bull Case Changed?

    Simply Wall St·11/13/2026 09:19:07
    Listen to the news
    • Vaxcyte reported third quarter 2026 results showing a net loss of US$297.06 million and a basic loss per share of US$1.99, with the nine month loss reaching US$901.99 million and US$6.25 per share.
    • The widening losses highlight how Vaxcyte’s late stage vaccine programs and manufacturing build out are weighing on the income statement during its pre revenue phase.
    • We will assess how Vaxcyte's larger third quarter net loss shapes the existing investment narrative around late stage vaccine development.

    Compare Vaxcyte’s heavy R&D spending with other pre revenue developers by scanning our curated list of 20 high quality undiscovered gems that are still flying under most investors’ radar.

    Vaxcyte Investment Narrative Recap

    For a shareholder in Vaxcyte, the main belief is that heavy R&D and manufacturing spend today will support a broad pneumococcal and Group A Strep franchise. The analyst consensus narrative on Simply Wall St centers on late stage programs such as VAX 31 and VAX A1 progressing cleanly. The latest quarterly loss reinforces that this is still a pre revenue, cash consuming story rather than a margin focused one.

    The near term catalyst remains clinical and regulatory progress for VAX 31 and related trials, not the earnings release itself, so the reported loss does not fundamentally change that focus. The biggest current risk is that rising trial and manufacturing expenses pull cash usage ahead of expectations and bring funding needs forward if timelines slip.

    The third quarter 2026 earnings announcement is the most relevant update for this context. It showed a quarterly net loss of US$297.06 million and a basic loss per share of US$1.99, with nine month losses at US$901.99 million and US$6.25 per share. For a business with no revenue, that scale of spending is the core operational factor to track.

    Those figures sit alongside a reported cash and investments balance of about US$3.0 billion and guidance for runway to at least the end of 2028 in the analyst consensus narrative on Simply Wall St. Near term catalysts such as OPUS studies or VAX 31 regulatory milestones sit on top of this funding base, while the risk side of the story is whether execution on large trials and new manufacturing keeps that runway intact.

    Vaxcyte's narrative projects US$748.4 million revenue and US$119.1 million earnings by 2029. This implies very large yearly revenue growth from zero revenue today and an earnings increase of about US$1.2b from current earnings of a US$1.1b loss.

    Uncover how Vaxcyte's fair value indicates an 81% potential upside to its current price that may not last much longer.

    NasdaqGS:PCVX 1-Year Stock Price Chart
    NasdaqGS:PCVX 1-Year Stock Price Chart

    Exploring Other Perspectives

    Some of the lowest analysts focus on commercial risk rather than just cash runway. They assume only about US$21.3 million of revenue and US$3.7 million of earnings by 2029, far below the consensus. You can read this as a much more cautious Vaxcyte story that the new loss and conference appearance might eventually reshape.

    Explore 2 other Vaxcyte fair value estimates, including one that suggests the potential for as much as 48% downside from the current price!

    The Verdict Is Yours

    Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

    Looking For More Investment Ideas Beyond Vaxcyte?

    Vaxcyte might be front of mind today, but your portfolio does not need to hinge on a single story. Use this moment to refresh your broader watchlist and line up a few other potential opportunities using the Simply Wall St Screener.